<SEC-DOCUMENT>0001628280-25-006430.txt : 20250219
<SEC-HEADER>0001628280-25-006430.hdr.sgml : 20250219
<ACCEPTANCE-DATETIME>20250219170055
ACCESSION NUMBER:		0001628280-25-006430
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250219
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20250219
DATE AS OF CHANGE:		20250219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		25641442

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20250219.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:16cb8d7f-75d4-4717-888e-de892581faf7,g:82634e3d-1612-4d82-a960-ea91edfe7341,d:5564f7b1cefb4bec9b4071476bbc43e4-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20250219</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20250219.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-19</xbrli:startDate><xbrli:endDate>2025-02-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5564f7b1cefb4bec9b4071476bbc43e4_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">February 19, 2025 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 19, 2025</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5564f7b1cefb4bec9b4071476bbc43e4_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2025, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221;) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone") announced the NMPA (National Medical Products Administration) approval of Cumberland&#8217;s Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to patients in that country. The NMPA is the Chinese pharmaceutical regulatory authority there, equivalent to the United States&#8217; Food and Drug Administration (FDA).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="vibativ-sciclonechinaappro.htm">Exhibit 99.1.</a></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:22.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vibativ-sciclonechinaappro.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vibativ-sciclonechinaappro.htm">Press release dated February 18, 2025</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i5564f7b1cefb4bec9b4071476bbc43e4_7"></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: February 19, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vibativ-sciclonechinaappro.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3d1dc30be28645a08cee4a71064dcd57_1"></div><div style="background-color:#ffffff"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:290px"><font style="color:#434343;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1.jpg" src="image_1.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:197px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIBATIV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECEIVES MARKETING APPROVAL IN CHINA</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%"> is a life-saving antibiotic for pneumonia and serious skin infections</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Approval in China paves the way for launch in world&#8217;s second-largest market</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">NASHVILLE, Tennessee, U.S. and SHANGHAI, China (February 18, 2025) &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Specialty pharmaceutical companies </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> (Nasdaq&#58; CPIX) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">SciClone Pharmaceuticals (Holdings) Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> (&#8220;SciClone Pharmaceuticals&#8221; or &#8220;SciClone&#8221;) today announced the NMPA (National Medical Products Administration) approval of Cumberland&#8217;s Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">to patients in that country. The NMPA is the Chinese pharmaceutical regulatory authority there, equivalent to the United States&#8217; Food and Drug Administration (FDA).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Vibativ is a potent, FDA-approved injectable anti-infective that serves as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and are multidrug-resistant. Vibativ is also used for the treatment of complicated skin and skin structure infections, such as MRSA. As a once-daily dosed antibiotic, it does not require therapeutic drug monitoring, decreasing health care professionals&#8217; exposure to the patient.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">While many recently introduced antibiotics are quickly losing the battle to fight the bacteria they were designed to kill because those bacteria have become drug-resistant, Vibativ was specifically designed to kill drug-resistant bacteria. Two published studies &#8211; one that tested over 24,000 clinical isolates and one that tested over 15,000 &#8211; show that Vibativ is just as potent today against difficult-to-treat and multidrug-resistant bacteria as it was when it was introduced over 10 years ago.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8220;Vibativ&#8217;s life-saving potential for patients with certain difficult-to-treat infections makes it an important addition to our portfolio and supports our mission to provide quality medical products that improve patient care,&#8221; said Zhao Hong, Executive Director, President and CEO of SciClone Pharmaceuticals. &#8220;We strongly believe in this product and look forward to providing it to patients in China.&#8221;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8220;SciClone has a strong distribution network throughout China, and we are proud to partner with them to introduce Vibativ for the benefit of patients in their market,&#8221; said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. &#8220;We are confident they will ensure the product reaches as many patients within the country as possible.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">SciClone and Cumberland plan to launch Vibativ in China later this year.</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">About Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:139%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> (telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">Staphylococcus aureus (S. aureus)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> and other Gram-positive bacteria, including MRSA and MSSA. It is a once-daily, injectable lipoglycopeptide antibiotic with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> potency, bactericidal activity within six hours and penetration into patients&#8217; target infection sites.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The drug is approved in the U.S., China and Middle East for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP&#47;VABP) caused by susceptible isolates of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">S. aureus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> when alternative treatments are not suitable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">In addition, Vibativ is approved for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">S. aureus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> and both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The product labeling also describes the use of Vibativ in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The product&#8217;s proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">S. aureus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> infections studied to date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Importantly, these studies demonstrated significantly higher cure rates for Vibativ as compared to vancomycin in HABP&#47;VABP due to any single Gram-positive pathogen or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">S. aureus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> with vancomycin MIC &#8805;1 &#181;g&#47;mL. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Additionally, there is extensive and well-documented evidence of the drug&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> potency and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</font></div><div style="margin-bottom:12pt;margin-top:14pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">In October 2023, Cumberland announced a new publication in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">Antimicrobial Agents and Chemotherapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ in children 2 to 17 years of age. The results of the study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">For full prescribing information, including important safety information visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">www.vibativ.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">About SciClone Pharmaceuticals</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:136%">SciClone Pharmaceuticals (Holdings) Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> (&#8220;SciClone Pharmaceuticals&#8221;) is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">With an innovation-driven strategic transformation, SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products &#47; pipelines. Staying true to its original aspiration of &#8220;SciClone gives life hope</font><font style="color:#b5082e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">&#8221; SciClone Pharmaceuticals is dedicated to improving patients' health by providing top-tier health</font><font style="color:#b5082e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">care products and services with global standards of care.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">For more information regarding SciClone Pharmaceuticals, please visit&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%;text-decoration:underline">www.sciclone.com</font><font style="color:#b5082e;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:136%">.</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">About Cumberland Pharmaceuticals</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Cumberland&#8217;s portfolio comprises six FDA-approved brands. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne muscular dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond its control as more fully discussed in the company&#8217;s most recent Form 10-K and any additional updates filed with the SEC. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">SOURCE&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals</font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;padding-right:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                             # # #</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt;padding-right:10.8pt;text-align:center"><font><br></font></div><div style="padding-left:14.4pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:3pt;padding-right:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumberland Contact&#58;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SciClone Pharmaceuticals Contact&#58;  </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div style="padding-right:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shayla Simpson</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mengxue Zhu</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molly Aggas</font></div><div style="padding-right:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SciClone Pharmaceuticals</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dalton Agency</font></div><div style="padding-right:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(615) 277-5118</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8621) 2319-3868</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(704) 641-6641</font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20250219.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:16cb8d7f-75d4-4717-888e-de892581faf7,g:82634e3d-1612-4d82-a960-ea91edfe7341-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20250219" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20250219">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250219_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250219_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20250219_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:16cb8d7f-75d4-4717-888e-de892581faf7,g:82634e3d-1612-4d82-a960-ea91edfe7341-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_377acf93-aaaa-4895-8659-fa6e8fbd9878_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b979085c-7896-43ea-a933-a117cc16575c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a3feff0d-40c7-4f7f-b490-cff12ab49801_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fc35d1ce-19ad-46bd-87e0-f92a760c2186_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c2885d63-1786-458b-9302-dcf49819ace9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f390fa71-961a-4794-a554-70de07757e1d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_325bbaac-d19e-4473-b031-f0ae665e4925_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_99e4f91b-0ecf-451e-8f52-d7a85ea3de70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d926ed8-b229-4684-9981-f957b45d2765_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_5b0feff7-3ef5-452a-a74a-c2f8915d6eef_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e7dea168-4075-4af6-95d0-30e32b6e6c1d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_753de47e-a426-4fac-b4c3-3ac2e0db775a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e9ec1131-f97d-420f-b44f-3d355378e87c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_62c682c2-cc89-4e44-99e6-48d717d152de_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7dc34701-caa7-447d-a8a6-db92fd590a53_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_97d2cfd2-e5d6-4853-b6b4-befdf55b4527_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c2538e2e-e03b-44e0-a85e-5d66599b8b41_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ab540353-ecd3-48bf-b848-fc1977074831_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3278c02f-9305-4d00-a928-fea955ad7989_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fae8170b-482c-4575-b00e-6634cba8737b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a8bd4c04-8d91-44bf-ada8-80f7f5786d18_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2136c20f-7639-4062-b1ab-26160d967ec7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c42d403a-860f-4564-a2b3-1e856dc17340_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20250219_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:16cb8d7f-75d4-4717-888e-de892581faf7,g:82634e3d-1612-4d82-a960-ea91edfe7341-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20250219.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aa55ce8a-829b-4a9c-803c-78882a76d09d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_DocumentType_aa55ce8a-829b-4a9c-803c-78882a76d09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_03dd77e5-ffb5-4d52-ae54-5a4305f25fd3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_DocumentPeriodEndDate_03dd77e5-ffb5-4d52-ae54-5a4305f25fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a0f64d94-4c0f-4d27-97ef-8f33f85b296f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityRegistrantName_a0f64d94-4c0f-4d27-97ef-8f33f85b296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ce36938a-0bc3-41c3-b1fa-21b399b5332b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityCentralIndexKey_ce36938a-0bc3-41c3-b1fa-21b399b5332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8c816ec6-8660-4830-8220-0ec155ff6896" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_AmendmentFlag_8c816ec6-8660-4830-8220-0ec155ff6896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a15d0d86-95eb-4c76-83cd-f7eea7336200" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a15d0d86-95eb-4c76-83cd-f7eea7336200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3aee6bdb-89d4-4a75-b9e6-2dadb16cf16a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityFileNumber_3aee6bdb-89d4-4a75-b9e6-2dadb16cf16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f1685d9e-adb0-42b6-8395-7b5c6df0598e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityTaxIdentificationNumber_f1685d9e-adb0-42b6-8395-7b5c6df0598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fdc75359-5a12-4f6b-ad6e-359793872682" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_CityAreaCode_fdc75359-5a12-4f6b-ad6e-359793872682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_240b0090-babe-409a-9cce-c0d0c32182a0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_LocalPhoneNumber_240b0090-babe-409a-9cce-c0d0c32182a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fa08f16f-bd53-400e-ab79-c5f239cdbb10" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_WrittenCommunications_fa08f16f-bd53-400e-ab79-c5f239cdbb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b43a254c-69d7-4ae6-b7b0-c03199974068" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_SolicitingMaterial_b43a254c-69d7-4ae6-b7b0-c03199974068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ede7ffb6-a300-429e-a64a-cf3b3d1dc9be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_PreCommencementTenderOffer_ede7ffb6-a300-429e-a64a-cf3b3d1dc9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_de3da0fb-ebce-4dac-a2d0-891e72911add" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_de3da0fb-ebce-4dac-a2d0-891e72911add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fbf84f26-0f0b-4c26-bd42-46415271be21" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_Security12bTitle_fbf84f26-0f0b-4c26-bd42-46415271be21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_808f853a-f399-4f3e-b354-e4de12f7a90e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_TradingSymbol_808f853a-f399-4f3e-b354-e4de12f7a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e81525f-19e5-4f96-80a9-97a91220d38e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_SecurityExchangeName_8e81525f-19e5-4f96-80a9-97a91220d38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_db399c37-386c-47fc-8d3a-c5d5999227af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityEmergingGrowthCompany_db399c37-386c-47fc-8d3a-c5d5999227af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_08d0f836-c8d8-4d00-b245-26e9f5ec1533" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityAddressAddressLine1_08d0f836-c8d8-4d00-b245-26e9f5ec1533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8acf7240-f836-4b99-a490-5792c0d46f23" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityAddressCityOrTown_8acf7240-f836-4b99-a490-5792c0d46f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e04e59ef-6153-4f8f-957e-d7e0f62d3867" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityAddressStateOrProvince_e04e59ef-6153-4f8f-957e-d7e0f62d3867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_944fe5ea-d274-47e3-b1f0-1972f4f17f22" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4f2a09d1-ae9d-44e5-b3b5-ac5696ac3a7b" xlink:to="loc_dei_EntityAddressPostalZipCode_944fe5ea-d274-47e3-b1f0-1972f4f17f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !! 2(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^^BBBOE3X
MT?M7>!?A7K<'@BQFA\2?$"]C1X] L[A=FF12MMCNM;N$W_8(6(/E1E'N9]K&
M&%U1F&U##UL1/DHTY3>[23=EI>3;LDNNOR\YDU&W,[=M6NWW_P!>9]5$@?>(
M'U('TZG]?_U5\;_M??MG?"7]D_X=W7B3Q7XHT1O%>J:EI'AKP9X02^@GUG7?
M$WB+5;31=)MTTZ*4W*VL=U?)<WT[HD<=I#,Q<L$1OE;]I[XJ?$>7X=C58O%F
MI:5-?V4TSP:,_P#9UO"&#%8XV3?<'8F!YAE0N1N*+DJ/XW_VGO$&O>(OCO\
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M?%C]CJUT3XA^#?#7C;2+6_\  \JWEKIOB?1K/6K*"["J4%S%;7L2S!20L@8
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MKZ/9ZSJVAW%P-&O;?4-/V:IHU[8:C#Y=U:P.?)NHS(%*2%E8J?R]B_X-V?\
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M+?LX?&+Q)X9U"ZTS7M)\#:M>:/J%C+'#=6MW&B"&:WGD#112Y;Y)9 40G<W
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M\\%K%';1373RR1P1I$C!%"C;HI7:O9O7?5Z^O?YCLG;1:;>7IV.$\?\ PO\
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>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,4# 2(  A$! Q$!_\0
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M[ASI_AI9]*TV+6T&JPS65J;BP>Y?R/WZ^'?A*YU'X1Z'X?\ B4MKXF\0^(?
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MNM7DEU&XEFN))&/S-^RGXW^)?['7PC\-_LX^*[CX;_M%>%OA;I9\*_"/XH^
M?C5\+_#WB#6_ NF.\7A;1/B#X1\?^)O#BZ-XET/2UMM&DU/PUK/B'2=7BM8+
MIELIW,->>:#_ ,$D_P#@FWKGC;Q3\/-%_P"%K7/B_P $6FD7OBG2G\3>*XH]
M%M=>A,^ARW.J7GAV#1W75K>.273TM[^=[N*"XDA1TMYFCZ"Z_P""0G_!.ZQ\
M8Z)\/;FY\=V_C7Q'H^M^(=$\,2_$6X35M4T#PW-I5IKNKVUD;(32:;IEUKVC
MVMW=;?*CGU.UBR7DP/BL75RR,<11P^8YOCZ%6L\8_KV71P]:=1[XBKR5Z[IR
MES-R]YMIJ\I:-;U<;XTNOA\1A>"O#NA5P]&.6T)T..L=3C]67+&&'C#_ %.E
M=1LFDI632M;6_P!"_ 3XC_$[4_'_ ,</C-\<?&/PCTP:[HOA?PY\$/@-X*^,
M_A_Q7_PBGAKPK'XBU+5]2\0Z]<W&D>';KQS\1]>UC3X]0O+&(Z3HVF>']$L#
MJDR6[W#?,W[/'@KXN3_\%)/CM^V-\:/#/P\M?#OQ ^%7A#X)_!M]%^-'@?Q-
MJ'PR^'_AV]E\1>)HO$.G)+:/+=>)_%WV6Y5?#,NJ1VMQ=W,,K^5</.VOKO\
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M;Q75_!J,""UF75/@)^RI#X8U7Q=>3_$-M%TCQ+#X/OA!IGCB?5!XCN=>MO#
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M!XA^76_''C#Q)J-]'#-J%S>2-?ZB^VXN(;"VM].TV$PV5K G4_L;WVG?"O\
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MA?\ L[7OQBN/VF_$OQZTKQMH>E_&KXP7=M=?#6^DTO2[+7O@_P##ZQT?PO\
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275T[:V$ P /2BEHK):)'6?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46099345058560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Feb. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 19,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ &HA36APX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( !J(4UHD'INBK0
M /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2
MY0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D
M1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#
M='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#B
MR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  :B%-:99!Y
MDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE
M+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WU
MV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R
M;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$
M7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@
M9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!
M3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+
M 0(4 Q0    ( !J(4UH'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ &HA36KOTU<[N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M&HA36IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  :B%-:GA)Q#F4$  "J$   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M&HA36I^@&_"Q @  X@P   T              ( !J P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  :B%-:EXJ[',     3 @  "P              @ &$
M#P  7W)E;',O+G)E;'-02P$"% ,4    "  :B%-:'#AEZC\!   \ @  #P
M            @ %M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &HA3
M6B0>FZ*M    ^ $  !H              ( !V1$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ &HA36F60>9(9 0  SP,  !,
M         ( !OA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  "!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20250219.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20250219.htm">cpix-20250219.htm</File>
    <File>cpix-20250219.xsd</File>
    <File>cpix-20250219_lab.xml</File>
    <File>cpix-20250219_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20250219.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20250219",
   "dts": {
    "inline": {
     "local": [
      "cpix-20250219.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20250219.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20250219_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20250219_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250219.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250219.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-25-006430-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-006430-xbrl.zip
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M+B"_@*:$44YAX<[$'4%805#+Y:+9K-O.UF*]RC$]JS8L4L=929UC,F )9E-
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M6'W!BSUIU/UC=WLMI>"2^@^6Y/_*U/P_4$L#!!0    ( !J(4UJ!<''V?@(
M &8'   1    8W!I>"TR,#(U,#(Q.2YX<V3-5%MOVC 4?N=7>'F>R04*"2I4
M6KM*E=A%7:OU;3+Q";&:V)GM%/CWLTU<H*Q5V=/RY)SS?>?FS^?\8EU7Z FD
M8H)/@[@?!0AX+BCCRVEP?W>-T^!BUNN=?\#XX=/M'%V)O*V!:W0I@6B@:,5T
MB70)Z*>0C^R)H.\5T860-<8S1[L4S4:R9:E1$B5G'N:]<A*/\D5*QP4>G]$A
M'H[C,4[3%#"%-$O.TK@@Q?CC<I(FH\$0!A3'HSC!0YHFF&2C" /)8J %C ?#
MV 5=JXG*2Z@),JUQ-5FK:5!JW4S"<+5:]5>#OI#+,(FB.'SX,O_AH$&'K1A_
M/$"O%[+R^$%HW0NBP,/SAJV?X68N"Y 5X;0IB:Q)/Q=U:%N.DC@+$-%:LD6K
MX=K,Y@H*TE9Z&K3\=TLJ5C"@9O 5V-$> /;<FL@EZ*^D!M60'-Z9>-9#R,Z$
MU8V0&O$C^G&;C"M->&[:W YR+G*BG3Y>I=@_['G8FK"YI4'<7RL:A/]0PV[4
MI]7@>:?7X((IR/M+\1128':$P[^G5Z_![0';PV%.PKG0CF\MG:UI&"_$UF!,
MMO")K_X6"J_>(TEV HZS+ N=UZC1D8G,I:C@;7#82-& U S4OIQ=@%)",0VL
MJ+&7SZ]&0M]4XB%'"0ZOP+I-!E!&QJ[?^:XA'T)O&A-"F7NH8#NB_[G_BBQ.
M[=]0H#JQ<4N\,W[$Z#3P.]:\Z,]<,[VYX7:ANH%Z7X LY?[VYNTUX IZ5SQ?
MCZ^(0L$X<YJ-W!<CO-O^>T<3%6W#HKVXS_[S\&6X%XE:!?0;G[GS2^ETY [R
M!C$G5=Y6I_-V9;U*ZXS^AKH7'!X^X>W_WC-WANWNF/7^ %!+ P04    "  :
MB%-:C58,HD(*  ",50  %0   &-P:7@M,C R-3 R,3E?;&%B+GAM;,V<76_;
M.!:&[_LKM-F;76!8BQ(IDD7;03?3#H+-M$&;8@8[6!@4/Q)A;"F0E2;Y]TO*
M=BK%DBU2L;J]:!2;/N]Y:3W2(2GF]<_WRT7P396KK,C?G,"7X4F@<E'(++]Z
M<_+U\@.@)S^_??'B]=\ ^.-?G\^#7PIQNU1Y%9R6BE=*!G=9=1U4URKXO2C_
MRK[QX&+!*UV42P#>UA\[+6X>RNSJN@JB,,+;9MMWRU<P$2F51 .")0*(0 (H
MI0I(15F$*=1<DY^N7M$HB9&*)8 )C "2- *<)2%0G$$EM2(Q@G7019;_]<K^
ME_*5"HR]?%7_^N;DNJIN7LUF=W=W+^_3<O&R**]F41C&LVWKDTWS^YWV=W'=
M&C+&9O6[CTU765=#$Q;._OCM_(NX5DL.LGQ5\5Q8@57V:E6_>%X(7M6]?C"O
MH+>%_0ULFP'[$C"]$\.7]RMY\O9%$*R[HRP6ZK/2@?WY]?-9KR2;V1:S7%W9
M[_9"E5DAOU2\K,YYJA8F^SI:]7"CWIRLLN7-0FU?NRZ5[@Z[*,M65)LELUG"
MQ&;Y]SZQV8CTGRG?:C?79TBNMOOQN7+<UZ<?GRW=2W.%4,=/N"$S.N7U"?4^
MEU.=NX]2HU,_?L;/=5H4%5],<%I\EVFDO+ OG)NCC8P-M.=B6NML+MV-5-5]
MI7*IUE?+5N@@DV].S-%<JFS^/J^RZN',W!K+FZ*L+]SF6E6IT^(VK\J'TT*J
M>4P(%YK%@)M_ %&& 4TP YHGBNI4,DKHO'H\Q><J!U^_;+.I)9WT3AQ\5SW\
MEFI5W)9B?><S.=B[_CJMM^L,@E8*/P5U$D%1!IM$ IO)Z]EW"^.[<3%UYRPF
M[Y="M-06MA0HRJ=N"^'J]CMI*V.WMKI2XN55\6UF(AG+$;('P![4@ V-/]OY
M6M^56P^\% =Z>=-B)@I3 ]U4H-7ANBR67F:KPNN,6'>Y2>G$?%U2E:;J[;#7
M<=:>FK*WY(LS<[6X_[=ZF*>,L)!B 0AE"4"QXJ8BC0W]$!(A8(()%FZX/U&8
M!O"-:%"K!D;6E>:G_3*4WQ%NO8@=;M0#SQXS(X!\&G%B!'L,[4+7U] 7LP_9
M0GV\7::JG/-8*ZU#"5 H"$#:#!)3Q$(@M(81-X<TA&Z$?0\^#5Q6+U@+NF+5
MZ(>A1/FY\X)IB#$/C'8=C""H$6QB>'9M['+3T<87F7=2FF]L5=_Q/I479?$M
M,XG.M8BQA$(!R+AA*$DEH$2%0+.(DR04$:2)&S[=0M.@M-%NE%I;?5>R>KIK
M*&7C.\&+. __'@#N-S<"QI[ $X.YW]XNI ?:NP/[18G;T@1^?R^NS9>L/O*E
MFHN(4BR3&$!"326):0I8'$9 "FWN<89>H=A04+L$C@SH5C+8:@96=#B5G7UR
MF,:Q3MTH=#3IA-X^)U[(=0:<#+5]=IJ([6WGCM9%:89[RZ4R^=D5BK/5ZE:5
MEW9RI_RDM2FC=,Q"S0D$+($<(,(0X!@C0$*I0D(P45 .Q>R0V)&1,_) -/2#
M=0+!.H.@3F$X@ =[[C",S]D?;F".Z@HG3(=Z]$+V8/#)\!UJLXGRX,^,+'$W
M/\ZS7,%Y'.$TY5P "9D"")$8I&$,@0ZY2A*L$(NP5WW;5)FXN-T<!%8[^)3[
MUK:M?G(L;'W=CZMJ!QOW+VJ[C(VO:%M1?TPYVV6LMY;M;#P2RU-S^*F\+.[R
M.6,*:093$"JA32T+%: :FUJ6<(H5CZ4BH1>4WS4F1M(*V^&6E?;$L=$_CC#Z
MN1Z'XB##_ACN6AH/82/FCT%PUU0O@!U-1^)W4:PJOOA/=E.OGV')HD1)"M(H
M8@ E% %F1I% ,TQ2A&5$$K_;8DMF8@C7VH$1]UIQ[.PH1Q2][8^C<:AS?R [
MC8UGLAWVQV#9::V7S.[6'I,\Q2(3697E5[]Q<^YG?#'':6C7,@B(E<;FMAAQ
MP GB0$2:,HAEHI0>/,6S$_[8$SR/@L%6T6%V9[<S!LSMC++H.+/CX,YM6J?7
MA-^DSFZXZ:9T>JVT)G3Z6[E#=%I\4^6[=%657%1S1:3B,*$ A<3PPW4"&)8A
MB$,51VFB$C%\[J85>9K[V%EN'XFMGTL(_JR'.&>56J[^.QRC=G<<)LC;I!L\
MM4SPYU:HWY 3.9W)>T'3CC09+YT&FJAT-W"GY/<RJRJ5V\F7VSQ;/U&\FA-L
MQEF(*,!1E "DN0 I$C&(N8A4*%-",!]*2Z?"D:G9: 9MT>&P=/?*86A&>W6#
MQ]&F$T)[K7BAU!UQ,J3V&FJBM;^A.V+V0?W%Q761;Q_'4$P)".U$(R,2H"BT
MCZ4@#6(98QP3JB@9_.#7T^!'!JN6"VH]Y\=2=OKA,$]CW+FAY&#,":,^!UX$
M[02;#)X^&TUN>MOXKW+#*+W,JH6:)Y%(:"0B( 1E "EDYR24N35122"1$$=F
M/.ZXPKT-?F1D:HV@T &,_I'^,]BJNR]O/W;&@.'/"(MNW+BZ\UK7?FICU)KV
M8[#)U[.?VNA:R]YIXS'PL1,2I>+U'!61(D8DA$!P3NP:EP2<\@3(E$5:8A9R
M' \>]S0"'QF:>@K9:CG.UK6\#QCD>#IR'.,,,^,VPNG(W&^ TPPTW?BF(_W6
M\*;K?7<4MKM-'S=8_<(K-3=55R2TC(#"TMY"< S2)$4@55IJC%.$(S*4B4Z%
M(\/QN(=V+1H8U<#*#L>DNU\.\S+:K1LXSD:=$-IKQHNE[HB30;774).N_0U]
M%Y,N^?V9-%$SO1DT;<I\$>&8JD@!%<:IN06I$-BE7&#@2S!C*4V1XU/X/4K3
M3,49\:"M[OF ?E]_'<;PV7K!#4?O#O!86CI@;L3J4E_DB1>8#AC<76,Z] %W
M;-^9:X"TUX$/"WXUYRE&86SNA4K(V-P54PU2BBC0 C)"0H)H/!C35N0C8_FH
M%5BQX1"VW1^&SMN3&V0#[3@AU9FZ%T+M2),ATVF@B4AW W<D+DMN_W3)EX=E
M6BSF<42H""-MGZ;' ,G0W+E89)!0G&',)6%T\'/UK<C'GG)8:P5KL>%(M-T?
M1L+;D^,<PS [3DATINZ%1#O29$AT&F@BT=W M[C[K*XRN]B45_7N"LT5A20T
MY1R-!$"88)"&H0))$B.1<DIBDKK5=&V!:4JY[YJ..TXZ^V1HW>;OU*M<&VK2
MHTCK=C*B-GL2<.*2K-O.;B76TV[TCI/FC@E.4XE$B "5#)I!DZG&N.04T% 3
MC0E-)!S\MT#Z98Z,V<[6BF?97C)J8\F/V5)R]+TD1]I%\O^P?\1MY\CS[!G9
M3I!<FH_.(Q@GPB[2DB1F (5)!%+(4Q E, DE2X@2SM.%-O!4LX16RWUJL+8^
M?$;0U9#G1.!>+UZS?\W$1TWZU8$FG^MKIM\UQ==ZW[?X>[]4Y96I)7\MB[OJ
MVN!VP_.'N4"11&', 4U"NU,C08!':0R@HCB1 I(8.>[4Z-29IA3<2@=K[6 C
M[EH2=O?4T,IPM'^O M'5ND>AN-?8B'JQ.^[$9>-><[O5X_[F?8@VOXUS<_3V
MQ?:5;/W'.]^^^!]02P,$%     @ &HA36H 2B$3!!@  0S$  !4   !C<&EX
M+3(P,C4P,C$Y7W!R92YX;6S-6FUOVS@2_MY?X?-]/<847T0R:++(9=M#<-EM
MT&:QB_MB\&5H"Y4E@U::Y-_?2(G;IDEVA4B+Z(ML2V/-S#./9H9#O?WI9E/.
MOD#:%75U-,\.Z'P&E:]#4:V.YK]=OB=Z_M/QFS=O_T'('__^>#[[N?97&ZB:
MV6D"VT"871?->M:L8?9[G3X77^SLHK1-K-.&D./N;Z?U]C85JW4S8Y3)O=C^
M:CK,<N]T4)$H&001*E-$:PTD@#9,ZBS:J/ZU.M0LYP)X(%F>,2*"9L2:G!*P
M)H,007&1=3<MB^KS87MP=@<S=*_:=3^/YNNFV1XN%M?7UP<W+I4'=5HM&*5\
ML9>>WXO?/)*_YIUT9HQ9=%>_BNZ*IP3QMMGBCU_./_DU;"PIJEUC*]\JV!6'
MN^[D>>UMTZ'^EW;-GI5H?Y&]&&E/$42'9P<WNS _?C.;W<&1ZA(^0IRUG[]]
M//NJ$F/I()6V"MNU31M[X.O-HA5:[..,E]Y53='<GE5M4#N+]]?0F^[NS>T6
MCN:[8K,M87]NG2 >S?VVN"%MV"G+3&O3/WO==_'-\FV"72O>7C_'$_>W;VW\
M6[R FP:J '?@[8TH:_] J&Q#5Z?]/TOKH.S.+@,4R],:GZ<3MVN2]<U21&:I
M"1FQ8 (1 B1QW$EBO<Q-;CVWRCT$K?5JAVYUD=Z!/UC57Q9X8XPX$^V7%E'1
MH?E(W1UT+[-[#\@ERBZME=*#MD0SXXBPQA--N2<*GTUF51[0IT%F?Z_MH=7?
MA_PD^5F= B3,37MU-OD'X7_\5-Q+++8VX8V(7Q?E5V-CJC=CQ*JI1T#N+BQH
M[GR&7D=("<+Y752>=:[SK,&,#9WD&!&_@%34^(2$GS&E+RD/02GT/4;T702)
MF1:D(-(*3F5D,@8^2N@?J.W% 39]#KP<RU<FPUV"_ BKHD6B:GZU&R0SC;D(
M!NNRIQ'M9XH8!9'HR'G4TC&3QT%<>$IK+RKPZ5)A,)*38,(I8I5L>8;5\.:_
M<+OTP'/#,:]1YSD1&1X<-F>$98X;XR3G;%@A>U)M+RZ(J7-A"):O3(833&JA
M36SO2[M::J^S''Q.=(Z]M]"<8IECE%#PF90QYMKD@TCP0%VOX,OI!O_EV$TB
M YSA0C!MZ]0A_@F!A]/Z"HE\>UH'3&B9##3HG!@)V.=XA8YQ'TA4 %9QGJ-1
M(^2#/S6B%T'RZ1)D;)PG09OW10F_=DNR);< N0N.:-.N[:U"7 SDA 4;'"[\
M8Y;;$3CR36,O0JBI$^*%"$XB^I?VYBP@5D4L[N8;]XZ@H5H& P3MQNS'7$MC
M(XERTN<A4FDTC$"%9]3WXH6>.B_&P/:527**;IPDL%UJB\$KR:7!Y5 [TXNY
M0P]R('A*87ND6*[9($Y\KZT7!<QT*?!BY%XYXNV<L[Q8U]4^I3%!':6&$H>"
M1%!CB?$>B*>!>LXRC?@,BOJ/&ON-E^AT0S\(PE<._^^I:!JH3NO-YJJZ3UN[
M9;148]:*Q 6)"R!*,7<Y98B7D7'C@W/9, X\J;8?$28\:!P.YBNSX5-=%KYH
MBFKU"[:YJ;#ET@ENF12>Y"8H['"PN7$*RYBGO-UN48+F>A 5'NOLQX,)#QL'
MPOC*)+A(T#(8*@_=U+S=<$D?(MJQA  J1NQ?+*=M)]/V-+FPQ$?N>,B"-VY8
ME_B\[GZDF/#8<218IT6.L]WN"M+WO@3@P=+H"#BL>")83RP+%!=(&2AFLLR&
M83M3?V5!/Z),>"8Y*L2O75# 7V%1O,V8NRR:$CMC%S4"DQ,::3LNP6\N".R1
M<Y%)IC('+!M63G[0V(\.$YY2#H+PE<-_F6S[JLJGVXVKRZ7&/DA+;DGDQN"J
MB ,B( 4!$2!C45E#AU6/!^KZ!7["T\>7@S>1A_[=C5_;:@7=!IL&C>R4D60&
M 1#1Y$13:XA!RS/&:. #!TQ/:>W'@0D/' =#.8FAX[L-I!52^3^IOF[66-RV
MMKI=AG8SS7-%N,X]$2IZH@,2W,L@L25F3-DQ-J^?5-Z/&).?. X'=A+\. D!
M(["[_S@O*LB65 <:-<^)UT%CDX.-L6-"$I:#B;+=D^/#7G-Y5G4_;DQX%#D.
MJ%-B1CM<_9 NZ^MJJ:V/B@E*.C^$PV)HA:%$*L,\#2*/;$1>?%/<[P6H"4\I
MQP!T2ISH=F(_I(M4?REPJ;0$BE 8B"3/VC%;U)$8J8 $!33F#(MBKL8CQ@_:
M^[%CPJ/+T:"=$D4NZEUCR_\5VVY3Q@@108(E@:GV37;HWNJAV$4I%D7,5&3#
MMK.>U]V/'A.>:(X$ZVCD>+MXA"16N,_';^XOM(?VG?OC-_\'4$L#!!0    (
M !J(4UI2U_+YJ1(  ))N   >    =FEB871I=BUS8VEC;&]N96-H:6YA87!P
M<F\N:'1M[5UM<]NVLOY^?P5N,K>U9R15\GOLG,SH.$[CTR3-1&ERYWPY Y*0
MA)HD6(*4HO[Z^^R"H"A'\EOJ2+ZUTW'U0@+@[K.+9Q<+^/FX2.(7S\=*1B_^
MZ_E_M]OBI0G+1*6%"',E"Q6)TNIT)#Y'REZ(=KNZZM1DLUR/QH78Z>[LB\\F
MO] 3Z;XO=!&K%[Z=YS^Y]\]_XDZ>!R::O7@>Z8G0T3^>Z-VH%X6[W4#M'!WL
M[<ON4:C4GCSL=0_VHC#:/_Q/[PENQ>7N'EO,8O6/)X$,+T:Y*=.H'9K8Y,=/
MA_SS9.&J1*?ML:)1'N]W.WM9<3+543$^[G6[_^.N?/%\:-("@\K1B7OI^JI[
M?/%<)R,AXP)C3>1(_:?;^3T;/1$V#R]_XCJM.CS8S[Z<)#(?80R!*0J3'.]C
M !.5%SJ4<5O&>I0>%^I+47U=C6WG63?[\L2-RS=9/>+>+OT[H6_:0YGH>';\
MXT>=*"O>J:GX8!*9_MBR,K5MJW(]=!=:_:<Z[NV@:WX[=:/;ZW9/8ITJ+Y[>
M#DE$B!^>]@ZZ)S?_[85V24:]KV346R:C_6=WDU'OV>$J&77YYUYEY)_YAKV?
MRB3(M?RV7F^KE[_;[T7C;;J !72QM*N/"I,=[W<."7",, >V$!Y+Y?>.K<.E
M6OYT_L_^Q_-/MP38S89PV#FZP1A.,F-UH4UZG*M8%GJB3DA.[;W.SM>&&4BK
MJ &&Y^'>R6TMXR^5W8>ST[/S3V<#\;;_X9>SC^?O?A;]]^\__/JI_T:<OQ.G
MK\_?]6^(DH/O HF>?RQN\5@7Z"V\VA7L/B.0Z( 4<T\@Z>W?:5BK<+/;.5KB
MT2\#YWYP<U<!"VV%%+$>JK:5$^(^,BUTH T>00Q-+K)4E8E)M<07D:!^36F%
MO="IT.E0A20'>U./=+318.MG66XF,L:#B=.Q3J7(Y 0=%F,EIG+&XHAEF89C
MNF)J\CCZX>G13N_P! )1H0$_B_&\RA8"SWVABMLXZH98?B]MH8>S[^^760KO
M^H/7G\[?O#EKB8\J396U2K7$;YU!AQ$P>-U_]_/K_GFK$M'6*Q7DI<QGHG?4
M8GZ\+5@JO>_E(I<K<Y"I4(.ES40VEGDB0U6R58K0))E,-7I:DP?GX9V62:#R
MF"3Z?F%\5IRG86>=DA-;[Z2-Y!\_/-T_.A&G[\__=YLUOTYQ#4)]&IM4?26L
MK=<FCN"V[+9XHQ.-$&Z]HB/H[W1/5HV7OX9EP)-<NK+Z9EL4)H*OD6F*@"]$
M1$K>Y]W;]WU2"SE;0/BMBAC*[W,3E6%A13]"]*=MD?,54)?W9&8HYDBKG=7]
MSJJ7J==MIM ;4:_U:KC @"<R#37DK-/?W0Q83QD=\1'Z\MKCU,+0Q+&98II-
MA1SERGT8J&*J5,K:G7LDTIHF.(L:0'2!^A+&I860!&<A,",9D:L1%*[R%MV4
MF$*QC48$ AV4A;LQ<P!Y>(I>Z]0!Z688*M1D2:_%6!;049D6^<RIE\U1.V)
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M#^_H $%='<%"A%,5U5X!3JO+0/N8%& KJ0UH*;?5\0"\@WU94.7#3T-;[PI
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M*P,_N;\)]Q/_+;K_ U!+ 0(4 Q0    ( !J(4UHHVG8Q80\  *1L   1
M          "  0    !C<&EX+3(P,C4P,C$Y+FAT;5!+ 0(4 Q0    ( !J(
M4UJ!<''V?@(  &8'   1              "  9 /  !C<&EX+3(P,C4P,C$Y
M+GAS9%!+ 0(4 Q0    ( !J(4UJ-5@RB0@H  (Q5   5              "
M 3T2  !C<&EX+3(P,C4P,C$Y7VQA8BYX;6Q02P$"% ,4    "  :B%-:@!*(
M1,$&  !#,0  %0              @ &R'   8W!I>"TR,#(U,#(Q.5]P<F4N
M>&UL4$L! A0#%     @ &HA36E+7\OFI$@  DFX  !X              ( !
MIB,  '9I8F%T:78M<V-I8VQO;F5C:&EN86%P<')O+FAT;5!+!08     !0 %
+ % !  "+-@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cpix-20250219_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20250219.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2025-02-19</startDate>
            <endDate>2025-02-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
